Full-Time

HR Generalist

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Mid, Senior

Somerset County, NJ, USA

This is a hybrid position, indicating that some in-office days are required.

Category
Human Resources
People & HR
Required Skills
Customer Service
Data Analysis

You match the following Legend Biotech's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor's degree in Human Resources, Business Administration, or related field.
  • 3-5 years of experience in HR operations or a similar role.
  • Strong attention to detail and accuracy, ensuring high-quality data management.
  • Experience working in a highly collaborative environment, contributing to the success of the team.
  • Ability to analyze data, documents, reports, etc., with meticulous attention to detail.
  • Ability to work through a problem with limited information and collaboratively drive towards solutions.
  • Ability to multi-task in a fast-paced environment while delivering on commitments.
  • Experience interacting with employees at various levels of the organization while consistently providing exceptional and professional customer service.
  • Strong understanding of HR principles, practices, and employment laws.
  • Excellent interpersonal and communication skills, with the ability to interact effectively with employees at all levels of the organization.
  • Detail-oriented with strong organizational and multitasking abilities.
  • Ability to maintain confidentiality and handle sensitive information with discretion.
  • Proficiency in Microsoft Office Suite and HRIS systems.
Responsibilities
  • Support the HR Business Partners in various HR programs, including talent acquisition, talent management, performance management, employee engagement, and employee relations.
  • Partner with HR Business Partners on performance management cycles, including launching and closing each cycle and providing regular reporting during the program.
  • Coaches and consults with managers on leave of absence, payroll, performance issues, and general/non-complex HR inquiries. Help determine root causes and recommend appropriate next steps consistent with company policies and state and federal laws.
  • Drive the open requisition process from beginning to end, from budget and headcount approval. Assist with maintaining requisitions and recruiting information.
  • Maintain employee records and HR databases. Generate HR reports and assist in analyzing HR metrics.
  • Act as a resource for employees regarding HR-related inquiries, policies, and procedures, ensuring timely and accurate responses.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their therapies, such as CAR-T, involve modifying a patient's own cells to enhance their ability to fight cancer. Unlike many companies that focus on a single technology, Legend Biotech explores various technologies to find effective treatments. They operate in the personalized medicine sector, discovering, developing, and bringing new therapies to market, generating revenue through licensing and sales. The company emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
  • New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
  • Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

What critics are saying

  • Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
  • Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
  • Financial strain from new R&D facility could affect operational focus if advancements lag.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

Global Culture Review
Oct 3rd, 2024
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.

Stock Titan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).